Sökning: WFRF:(Godina Christopher) >
Prognostic impact o...
-
Godina, ChristopherLund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Cancerepidemiologi & strål,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Cancerepidemiology and radiation,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
(författare)
Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer : A prospective cohort study
- Artikel/kapitelEngelska2021
Förlag, utgivningsår, omfång ...
-
2021-10-04
-
Oxford University Press (OUP),2021
-
12 s.
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:b5c8f95d-f969-40b4-8392-69b1887ac4bc
-
https://lup.lub.lu.se/record/b5c8f95d-f969-40b4-8392-69b1887ac4bcURI
-
https://doi.org/10.1093/carcin/bgab090DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
The prognostic impact of insulin-like growth factor binding protein 7 (IGFBP7) in breast cancer is unclear. Host factors, including lifestyle, anthropometry and metabolic profile, might influence tumor-specific IGFBP7. This study aimed to investigate whether IGFBP7 levels and messenger ribonucleic acid (mRNA) expression are associated with the patient and tumor characteristics and prognosis in breast cancer. Patients with primary breast cancer in Lund, Sweden, were included preoperatively in the study between 2002 and 2012 (n = 1018). Tumor-specific IGFBP7 protein levels were evaluated with immunohistochemistry using tissue microarrays in tumors from 878 patients. IGFBP7 mRNA expression and its corresponding clinical data were obtained from The Cancer Genome Atlas and analyzed for 809 patients. Tumor-specific IGFBP7 protein levels were categorized based on Histo 300 scores into IGFBP7low (6.2%), IGFBP7intermediate (75.7%) and IGFBP7high (18.1%). Both low IGFBP7 protein levels and mRNA expression were associated with less aggressive tumor characteristics. Overall, IGFBP7low conferred low recurrence risk. The prognostic impact of IGFBP7high varied according to any alcohol consumption and tamoxifen treatment. IGFBP7high was associated with low recurrence risk in alcohol consumers but high recurrence risk in alcohol abstainers (Pinteraction= 0.039). Moreover, the combination of IGFBP7high and estrogen receptor-positive tumors was associated with low recurrence risk only in tamoxifen-treated patients (Pinteraction= 0.029). To conclude, IGFBP7low might be a good, independent prognosticator in breast cancer. The prognostic impact of IGFBP7high depends on host factors and treatment. IGFBP7 merits further investigation to confirm whether it could be a suitable biomarker for treatment selection.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Khazaei, SomayehLund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Epidemiologi och farmakogenetik,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Epidemiology and pharmacogenetics,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)so6710kh
(författare)
-
Tryggvadottir, HelgaLund University,Lunds universitet,Epidemiologi och farmakogenetik,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Epidemiology and pharmacogenetics,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)med-htg
(författare)
-
Visse, EdwardLund University,Lunds universitet,Glioma immunterapigrupp,Forskargrupper vid Lunds universitet,Glioma immunotherapy group,Lund University Research Groups,Skåne University Hospital(Swepub:lu)wbl-evi
(författare)
-
Nodin, BjörnLund University,Lunds universitet,Personlig patologi och cancerbehandling,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Personalized Pathology & Cancer Therapy,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)immu-bnn
(författare)
-
Jirström, KarinLund University,Lunds universitet,Terapeutisk patologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Therapeutic pathology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)pat-kji
(författare)
-
Borgquist, SigneLund University,Lunds universitet,Bröstcancer - prevention & intervention,Forskargrupper vid Lunds universitet,Breast cancer prevention & intervention,Lund University Research Groups,Aarhus University,Skåne University Hospital(Swepub:lu)ront-sbo
(författare)
-
Bosch, AnaLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Molekylära behandlingsstrategier vid bröstcancer,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Molecular therapeutics in breast cancer,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)med-abp
(författare)
-
Isaksson, KarolinLund University,Lunds universitet,Lunds Melanomstudiegrupp,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Lund Melanoma Study Group,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Central Hospital Kristianstad(Swepub:lu)kir-kis
(författare)
-
Jernström, HelenaLund University,Lunds universitet,Epidemiologi och farmakogenetik,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Epidemiology and pharmacogenetics,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)onk-hje
(författare)
-
LUCC: Lunds universitets cancercentrumÖvriga starka forskningsmiljöer
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Carcinogenesis: Oxford University Press (OUP)42:11, s. 1314-13250143-33341460-2180
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Godina, Christop ...
-
Khazaei, Somayeh
-
Tryggvadottir, H ...
-
Visse, Edward
-
Nodin, Björn
-
Jirström, Karin
-
visa fler...
-
Borgquist, Signe
-
Bosch, Ana
-
Isaksson, Karoli ...
-
Jernström, Helen ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Carcinogenesis
- Av lärosätet
-
Lunds universitet